Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (BSGM) on September 8, 2025. The filing reports the entry into a material definitive agreement with Monetary Metals & Co. ("MM"). The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics and Agreement Terms
The filing details a strategic partnership rather than historical financial performance. Key economic terms include:
- Revenue Share: MM will pay BioSig a quarterly revenue share on supplied gold deployed in "Passing Leases" on a sliding scale from 0.35% to 0.50%, depending on total kilograms leased.
- Purchase Incentives: MM will provide a discounted fee and quarterly cash rebate on BioSig's gold purchases based on a tiered schedule ranging from 0.75% to 0.20% of aggregate quarterly purchase volume.
- Yield Threshold: Leases must generate a net yield of at least 3% per annum after origination fees to qualify.
- Volume Obligations: BioSig must supply at least 10% of total leased ounces presented by MM that meet specific criteria. MM must offer passing leases equal to at least 90% of the gold under management supplied by BioSig.
Note: The filing does not provide current revenue, profit, cash flow, debt, or liquidity figures for BioSig Technologies, Inc.
Material Changes and Strategic Shift
The primary material change is the execution of a Tokenized Yield Partnership Agreement effective September 8, 2025. This agreement establishes an exclusive, multi-year partnership to design, launch, and distribute blockchain-based financial products tokenizing yield from MM's precious-metal lease and bond programs.
- Exclusivity: For at least three years, MM cannot tokenize yield from its precious-metal products with other parties, and BioSig cannot partner with third parties to tokenize yield from precious-metal leases.
- Term: The initial term is three years, subject to automatic one-year renewals unless terminated.
- Intellectual Property: BioSig will own all IP arising from the design and development of the tokenized yield products.
Outlook, Risks, and Contingencies
Management has entered this agreement to expand into blockchain-based financial products. Key risks and contingencies include:
- Performance Conditions: BioSig's retention of exclusivity is conditional on meeting quarterly supply thresholds. Failure to meet these thresholds after a 90-day cure period results in the loss of exclusivity, though it does not obligate the company to commit capital or continue participation.
- Termination: Either party may terminate for convenience with six months' notice or for customary breach and insolvency events.
- Compliance: Leases must not involve "Prohibited Persons" or borrowers in "Restricted Nations."
Investor Verification Checklist
- Verify the full text of the Tokenized Yield Partnership Agreement (Exhibit 10.1) for detailed definitions of "Passing Leases" and "Prohibited Persons."
- Confirm BioSig's current gold inventory and ability to meet the 10% quarterly supply threshold required to maintain exclusivity.
- Review the press release (Exhibit 99.1) for additional market context on the tokenized product launch timeline.
- Assess the financial impact of the 0.35% to 0.50% revenue share relative to BioSig's existing revenue streams.